PPARA and metabolic dysfunction-associated steatotic liver disease: This circRNA-based gene therapy is proposed to induce the resolution of hepatic steatosis and lipid peroxidation in NAFLD patients via an impact on circRNA_0046367/miR-34a/PPARα axis.